Bvf Partners L. P/Il Acquires 1,505,932 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Bvf Partners L. P/Il bought 1,505,932 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was bought at an average price of $9.84 per share, for a total transaction of $14,818,370.88. Following the purchase, the director now directly owns 4,688,954 shares of the company’s stock, valued at $46,139,307.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Olema Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ OLMA opened at $12.15 on Friday. The business’s 50 day moving average price is $9.75 and its 200 day moving average price is $7.00. Olema Pharmaceuticals, Inc. has a 52 week low of $2.19 and a 52 week high of $13.33.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Tuesday, August 8th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.24. On average, sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on OLMA shares. HC Wainwright lifted their target price on Olema Pharmaceuticals from $22.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. Credit Suisse Group boosted their price target on Olema Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. JPMorgan Chase & Co. boosted their price target on Olema Pharmaceuticals from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. Finally, Oppenheimer restated an “outperform” rating and set a $21.00 price target on shares of Olema Pharmaceuticals in a research note on Wednesday, September 6th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Olema Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $20.60.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. New York Life Investment Management LLC lifted its holdings in Olema Pharmaceuticals by 12.7% in the fourth quarter. New York Life Investment Management LLC now owns 133,157 shares of the company’s stock valued at $326,000 after acquiring an additional 15,008 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Olema Pharmaceuticals by 197.7% during the 1st quarter. Tower Research Capital LLC TRC now owns 29,150 shares of the company’s stock valued at $101,000 after buying an additional 19,358 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Olema Pharmaceuticals by 122.5% during the 4th quarter. GSA Capital Partners LLP now owns 231,633 shares of the company’s stock valued at $568,000 after buying an additional 127,549 shares in the last quarter. Sectoral Asset Management Inc. lifted its holdings in Olema Pharmaceuticals by 63.3% in the 4th quarter. Sectoral Asset Management Inc. now owns 1,441,805 shares of the company’s stock valued at $3,532,000 after purchasing an additional 558,749 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Olema Pharmaceuticals in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 88.00% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.